

Academic Webinar Series



Title

How the ICH E9 addendum around estimands may impact our clinical trials

Abstract

The way we think about clinical trial design, conduct and analysis is likely to undergo a step-change thanks to the much anticipated release of the draft ICH E9 addendum on estimands. Importantly, this topic is not only statistical. It is a multidisciplinary effort that requires a common understanding and buy-in beyond the statistics community. Prior to the release of the guidance document, expected in mid-2017, Dr. Bretz will discuss where we currently stand and postulate on possible future directions.

Professional Biography

Dr. Bretz joined Novartis in 2004, where he is currently Global Head of the Statistical Methodology and Consulting group. He has supported the methodological development in various areas of drug development, including dose finding, multiple comparisons, and adaptive designs. Frank is currently holding Adjunct/Guest professorial positions at the Hannover Medical School (Germany), Shanghai University of Finance and Economics (P.R. China), Medical University of Vienna (Austria) and Osaka University (Japan).

Sponsored by

- American Statistical Association (Connecticut Chapter)
- Boehringer Ingelheim Pharmaceuticals, Inc. (Biostatistics and Data Sciences Department)

Frank Bretz, Ph.D.

Global Head,
Statistical Methodology
and Consulting Group,
Novartis

**August 17th,
Thursday
9-10 am EST**

For more information
regarding upcoming
webinar schedule,
please contact:
medecc.us@boehringer-ingelheim.com

